Natera

Natera's 15min chart triggered RSI Oversold, KDJ Golden Cross.

Natera Executives Sell Shares Amid Recent Decline in Stock Price

Natera Oversold: Warren Buffett Indicator Signals Potential Buying Opportunity

Natera's MACD Death Cross and Bearish Marubozu signal bearish trend continuation.

Natera Executives Sell Shares Amid Recent Price Surge

Catalyst<ul> <li>Most analysts rate NTRA Buy or Strong Buy, showing broad institutional optimism.</li> <li>Recent MACD Golden Cross and Long Lower Shadow signals indicate strong bullish momentum for NTRA.</li></ul>Risk<ul> <li>RSI Overbought conditions suggest potential bearish bias and possible price correction.</li> <li>Fund flows show negative trends across small, medium, and large orders, indicating weak investor confidence.</li></ul>

Key Factors

Natera (NTRA) insiders sold over 80,000 shares in early February 2026, including large transactions by CEO Steven Leonard Chapman and other executives. Natera submitted its FDA PMA application for the Signatera CDx test, creating regulatory uncertainty and mixed market reactions. Natera's stock price dropped to a 52-week low of $204.86, with RSI entering oversold territory and a bullish reversal signal from KDJ indicators on February 5, 2026.

NTRA News